BioMedNewsBreaks

FridayMar 24, 2023 12:20 pm

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) NanoAb Holds Potential to Combat New COVID-19 Variants

BiondVax (NASDAQ: BVXV) is a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. “BiondVax is seeing convincingly positive outcomes for preventing and arresting disease in COVID patients during an ongoing preclinical in vivo study, even as continually evolving variants are shutting down emergency-use authorization (‘EUA’)-approved avenues of treatment that may no longer be effective… However, BiondVax’s development of a nanosized antibody (‘NanoAb’), that to date has shown neutralization of all relevant Omicron subvariants, is generating excitement as a potential superior prophylactic approach to COVID prevention… At-risk groups, such…

Continue Reading

FridayMar 24, 2023 12:00 pm

BioMedNewsBreaks – Why Progressive Care Inc. (RXMD) Is ‘One to Watch’

Progressive Care (OTCQB: RXMD) is an organization based in Florida that, through its wholly owned subsidiaries PharmcoRx Pharmacy and ClearMetrX, offers personalized care services and technology to support the managed health care industries. “Progressive Care offers a wide range of innovative solutions to address the dispensing, delivery, dosing and reimbursement of clinically intensive, high-cost drugs. Progressive Care currently operates four pharmacies in Florida, which generate the majority of its revenue,” reads a recent article. “Pharmacy revenue is derived from dispensing medications, third-party administrative services to 340B-covered entities, and medication therapy management (‘MTM’) services. The company also provides customized management, patient…

Continue Reading

FridayMar 24, 2023 11:41 am

BioMedNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Positioned as Frontrunner in Psychedelic Drugs Market

Silo Pharma (NASDAQ: SILO) is a developmental-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research. “Silo Pharma has distinguished itself amongst peers for its ground-breaking research into conditions such as post-traumatic stress disorder (‘PTSD’), fibromyalgia, Alzheimer’s disease, and other rare neurological disorders. The company has recently entered into a number of studies designed to develop innovative solutions for previously underserved conditions,” a recent article reads. This comes as a recent study found that psychedelic drugs could show promise as a therapeutic alternative in treating drug-resistant depression. “What the study found was that psychedelics were increasingly able to access…

Continue Reading

FridayMar 24, 2023 11:24 am

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Poised to Enable Expedited Care for Heart Attack Patients

HeartBeam (NASDAQ: BEAT) is developing the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere. “By applying a suite of proprietary algorithms to simplify vector electrocardiography (‘VECG’), the HeartBeam platform will enable patients and their clinicians to determine quickly and easily if symptoms are due to a heart attack so care can be expedited if required. HeartBeam has two patented products in development. HeartBeam AIMI(TM) is software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to identify a heart attack more accurately. HeartBeam AIMIGo(TM) is the first and only credit-card-sized,…

Continue Reading

WednesdayMar 22, 2023 12:58 pm

BioMedNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) to Attend Investor Summit

IGC Pharma (NYSE American: IGC) (aka India Globalization Capital Inc.) today announced that its Chief Executive Officer Ram Mukunda and Principle Financial Officer Claudia Grimaldi will attend the Investor Summit on Wednesday, March 29, 2023. According to the update, Mukunda and Grimaldi will deliver a virtual company presentation at 11:30 a.m. ET and be available for virtual one-on-one meetings throughout the day. Interested investors should visit https://ibn.fm/AiqIk to register for the webinar and view the live presentation. To view the full press release, visit https://ibn.fm/M3rGV About IGC Pharma Inc. IGC Pharma is a clinical stage biotechnology company developing advanced cannabinoid-based…

Continue Reading

WednesdayMar 22, 2023 12:47 pm

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Subsidiary Receives Official Approval to Move Forward with Phase 1 Clinical Trial

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, announced that its Australian entity, FSD Pharma Australia Pty Ltd., has been approved to move forward with a key phase 2 clinical trial. The approval comes from the Alfred Ethics Committee in Australia, and the trial is designed to evaluate FSD Pharma’s Lucid-201 as a novel drug candidate for the potential treatment of major depressive disorder (“MDD”). Lucid-Psych is being developed outside of Australia by Lucid Psycheceuticals Inc.,…

Continue Reading

WednesdayMar 22, 2023 10:08 am

BioMedNewsBreaks – Coeptis Therapeutics Holdings Inc. (NASDAQ: COEP) Tech Spotlighted in Article in Peer-Reviewed Translational Medicine Journal

Coeptis Therapeutics (NASDAQ: COEP), a biopharmaceutical company developing innovative cell therapy platforms for cancer, was spotlighted in the peer-reviewed “Journal of Translational Medicine.” The company’s SNAP-CAR technology was recognized in an article that detailed advances in modulating chimeric antigen receptor (“CAR”)-T cell activity for improved safety, efficacy and flexibility. SNAP-CAR is a multiantigen chimeric antigen receptor T cell technology that can be adapted to different cancer indications, including hematologic and solid tumors. Titled “Tuning CARs: Recent Advances In Modulating Chimeric Antigen Receptor (‘CAR’) T Cell Activity for Improved Safety, Efficacy and Flexibility,” the article outlined the efforts and collaborations that…

Continue Reading

MondayMar 20, 2023 1:05 pm

BioMedNewsBreaks – India Globalization Capital Inc. (NYSE American: IGC) Rebrands, Including Changing Name to IGC Pharma, as Part of ‘Major Milestone’ Alignment

India Globalization Capital (NYSE American: IGC) (dba IGC Inc.) will begin operating under the name IGC Pharma Inc. (dba IGC), effective March 30, 2023; the name change is one aspect of the company’s rebranding strategy designed to better reflect its strategic focus and vision for the future. IGC’s common stock will trade on NYSE American exchange under the new name on March 31, 2023; the symbol will remain the same: IGC. According to the announcement, the change in name to IGC Pharma better represents the company’s focus as a developer of drug assets for treating diseases, including but not limited to…

Continue Reading

FridayMar 17, 2023 10:40 am

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Releases Q4, FY 2022 Financial Report, Corporate Updates

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform for heart attack detection anytime, anywhere, is reporting its operational and financial results for the fourth quarter and full year, ended Dec. 31, 2022. The company has also scheduled an earnings call and webcast for today at 4:30 p.m. ET to discuss the report. A highlight of the report includes the company’s strategic acquisition of LIVMOR assets, including its FDA-cleared Halo+(TM) Atrial Fibrillation Detection System and physician-prescribed integrated patient care platform, three U.S. patents, business contracts and relationships as well as all…

Continue Reading

ThursdayMar 16, 2023 3:44 pm

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) CEO to Present at BIO-Europe Spring

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today announced that its CEO Amir Reichman will be presenting in-person at the 17th annual BIO-Europe Spring. The event is slated to take place from March 20–22, 2023, in Basel, Switzerland, and draw over 2,800 executives from biotech, pharma and finance companies to engage in 15,000+ one-to-one meetings. Reichman’s presentation will begin at 11:30 a.m. on Tuesday, March 21, and focus on recent successful preclinical in vivo results of BiondVax’s innovative inhaled COVID-19 treatment and additional…

Continue Reading